Literature DB >> 29622863

Summary and Review of the Abstracts on Philadelphia-Negative Myeloproliferative Neoplasms Presented at Haematocon 2017.

Tathagata Chatterjee1, Ankur Ahuja1.   

Abstract

There are lot of grey zones in Philadelphia negative chronic myeloproliferative neoplasms (CMPNs) and that's the reason they are in hit list of researchers. Having a spectrum of disorders their diagnosis is very important and especially to differentiate from each other since they overlap with each other in many ways. Diagnosis doesn't start from lab but with clinical phenotype. Clinical phenotype not only able to provide us the diagnosis but also helps in management of the disease per se. When diagnosis comes, the old timer but an evergreen morphology plays an important role which along with the newer generation tool "molecular" helps in differentiating these disorders. Lot of studies have already come up from the world. Indian data has also started coming up. When we say about the Indian data nothing holds more important role than Indian Society of Haematology and Blood Transfusion, ISHBT. This small review will cover all papers with BCR-ABL negative CMPNs which were presented at the annual national conference of the ISHBT (Haematocon 2017) which was conducted at Guwahati. These abstract papers from various reputed institutes and centres will provide a short academic journey towards ongoing research activities at these places and will able to guide us regarding Philadelphia negative CMPNs and also stimulate our brain for some left or conflicted areas.

Entities:  

Keywords:  Chronic myeloproliferative neoplasm; JAK 2 mutation in CMPN; Megakaryocyte morphology in CMPN; Philadelphia negative; Thrombophilia in CMPN

Year:  2018        PMID: 29622863      PMCID: PMC5885002          DOI: 10.1007/s12288-017-0913-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  29 in total

1.  BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2.

Authors:  G C Shepard; H L Lawson; G A Hawkins; J Owen
Journal:  Int J Lab Hematol       Date:  2010-12-01       Impact factor: 2.877

2.  Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  R McClure; M Mai; T Lasho
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

3.  Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis.

Authors:  Gurunathan Murugesan; Samer Aboudola; Hadrian Szpurka; Mary Ann Verbic; Jaroslaw P Maciejewski; Raymond R Tubbs; Eric D Hsi
Journal:  Am J Clin Pathol       Date:  2006-04       Impact factor: 2.493

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

Review 6.  Thrombotic disease in the myeloproliferative neoplasms.

Authors:  Anna Falanga; Marina Marchetti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

7.  The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.

Authors:  Martyna Borowczyk; Marzena Wojtaszewska; Krzysztof Lewandowski; Lidia Gil; Maria Lewandowska; Agata Lehmann-Kopydłowska; Renata Kroll-Balcerzak; Andrzej Balcerzak; Małgorzata Iwoła; Michał Michalak; Mieczysław Komarnicki
Journal:  Thromb Res       Date:  2014-11-15       Impact factor: 3.944

8.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

Authors:  Jaroslav Jelinek; Yasuhiro Oki; Vazganush Gharibyan; Carlos Bueso-Ramos; Josef T Prchal; Srdan Verstovsek; Miloslav Beran; Elihu Estey; Hagop M Kantarjian; Jean-Pierre J Issa
Journal:  Blood       Date:  2005-07-21       Impact factor: 22.113

9.  Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.

Authors:  J Thiele; S Funke; S Holgado; H Choritz; A Georgii
Journal:  Anal Quant Cytol       Date:  1984-09

10.  Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).

Authors:  Shixiang Zhao; Xiang Zhang; Yang Xu; Yufeng Feng; Wenhong Sheng; Jiannong Cen; Depei Wu; Yue Han
Journal:  Int J Med Sci       Date:  2016-01-25       Impact factor: 3.738

View more
  1 in total

1.  Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera.

Authors:  Shrinidhi Nathany; Sindhura Lakshmi Koulmane Laxminarayana; Siddharth Tewari; Sushma Belurkar; Ruchee Khanna; Chethan Manohar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-09       Impact factor: 0.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.